Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Datopotamab deruxtecan + DS-3201b |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DS-3201b | DS-3201|Valemetostat Tosylate | EZH1 inhibitor 5 EZH2 inhibitor 20 | DS-3201b inhibits EZH1 and EZH2, resulting in decreased H3K27 trimethylation and potentially leading to decreased tumor growth (Blood 2017 130:2073, PMID: 30658046). | |
Datopotamab deruxtecan | Dato-DXd|DS1062a|DS 1062a|DS-1062a | TROP2 Antibody 13 | Datopotamab deruxtecan (DS-1062a) is an antibody-drug conjugate (ADC) comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06244485 | Phase I | DS-3201b + Trastuzumab deruxtecan Datopotamab deruxtecan + DS-3201b | A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors | Recruiting | USA | 1 |